[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100398760":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":36,"centralContacts":41,"locations":47,"responsibleParty":167,"collaborators":169,"id":178,"slug":179,"hasResults":180,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":10,"eligibilityCriteria":184,"healthyVolunteers":185,"sex":186,"minAge":187,"maxAge":10,"enrollmentInfo":188,"targetDuration":10,"studyType":191,"phases":10,"briefSummary":192,"conditions":193,"keywords":10,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":204},{"fullName":5,"class":6},"University of Washington","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Screening (biospecimen collection)",null,"Participants undergo collection of blood, urine, and\u002For tissue samples every 12 months, when any biopsy occurs, and if relevant, at time of curative therapy and 12 months after completion of curative therapy.",[13,14,15,16],"Procedure: Biospecimen Collection","Other: Laboratory Biomarker Analysis","Other: Quality-of-Life Assessment","Other: Questionnaire Administration",[18,23,27,33],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"PROCEDURE","Biospecimen Collection","Undergo collection of blood, urine, and\u002For tissue samples",[9],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Laboratory Biomarker Analysis","Correlative studies",[9],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Quality-of-Life Assessment","Ancillary studies",[9],[32],"Quality of Life Assessment",{"type":6,"name":34,"description":29,"armGroupLabels":35,"otherNames":10},"Questionnaire Administration",[9],[37],{"name":38,"affiliation":39,"role":40},"Heather H. Cheng, MD, PhD","Fred Hutch\u002FUniversity of Washington Cancer Consortium","PRINCIPAL_INVESTIGATOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":10,"email":46},"Study Team Coordinator","CONTACT","206-210-4040","patrol@uw.edu",[48,65,80,99,112,128,144,155],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"City of Hope","RECRUITING","Duarte","California","91010","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-117.97729,34.13945,{"lat":60,"lon":59},[63],{"name":64,"role":40,"phone":10,"phoneExt":10,"email":10},"Joanne Jeter, MD",{"facility":66,"status":50,"city":67,"state":52,"zip":68,"country":54,"countryCode":55,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"University of California, San Francisco","San Francisco","94143",{"type":57,"coordinates":70},[71,72],-122.41942,37.77493,{"lat":72,"lon":71},[75,78],{"name":76,"role":44,"phone":10,"phoneExt":10,"email":77},"Ada Sanchez","ada.sanchez@ucsf.edu",{"name":79,"role":40,"phone":10,"phoneExt":10,"email":10},"Matthew Cooperberg, MD, MPH",{"facility":81,"status":50,"city":82,"state":83,"zip":84,"country":54,"countryCode":55,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Northwestern","Chicago","Illinois","60611",{"type":57,"coordinates":86},[87,88],-87.65005,41.85003,{"lat":88,"lon":87},[91,94,97],{"name":92,"role":44,"phone":10,"phoneExt":10,"email":93},"Sophia Kallas","Sophia.kallas@northwestern.edu",{"name":95,"role":96,"phone":10,"phoneExt":10,"email":10},"Edward Schaeffer, MD, PhD","SUB_INVESTIGATOR",{"name":98,"role":40,"phone":10,"phoneExt":10,"email":10},"Hiten Patel, MD, MPH",{"facility":100,"status":50,"city":101,"state":102,"zip":103,"country":54,"countryCode":55,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":57,"coordinates":105},[106,107],-71.05977,42.35843,{"lat":107,"lon":106},[110],{"name":111,"role":40,"phone":10,"phoneExt":10,"email":10},"Keyan Salari, MD, PhD",{"facility":113,"status":50,"city":114,"state":115,"zip":116,"country":54,"countryCode":55,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"OHSU Knight Cancer Institute","Portland","Oregon","97239",{"type":57,"coordinates":118},[119,120],-122.67621,45.52345,{"lat":120,"lon":119},[123,127],{"name":124,"role":44,"phone":125,"phoneExt":10,"email":126},"Alexandra Sokolova, MD","503-418-8150","cedartrials@ohsu.edu",{"name":124,"role":40,"phone":10,"phoneExt":10,"email":10},{"facility":129,"status":50,"city":130,"state":131,"zip":132,"country":54,"countryCode":55,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"University of Pennsylvania\u002FAbramson Cancer Center","Philadelphia","Pennsylvania","19104",{"type":57,"coordinates":134},[135,136],-75.16362,39.95238,{"lat":136,"lon":135},[139,143],{"name":140,"role":44,"phone":141,"phoneExt":10,"email":142},"Kara Maxwell, MD, PhD","215-615-3004","PATROL@pennmedicine.upenn.edu",{"name":140,"role":40,"phone":10,"phoneExt":10,"email":10},{"facility":145,"status":146,"city":147,"state":148,"zip":149,"country":54,"countryCode":55,"cosmosGeoPoint":150,"geoPoint":154,"contacts":10},"University of Texas Health Science Center at San Antonio","TERMINATED","San Antonio","Texas","78229",{"type":57,"coordinates":151},[152,153],-98.49363,29.42412,{"lat":153,"lon":152},{"facility":39,"status":50,"city":156,"state":157,"zip":158,"country":54,"countryCode":55,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"Seattle","Washington","98109",{"type":57,"coordinates":160},[161,162],-122.33207,47.60621,{"lat":162,"lon":161},[165,166],{"name":43,"role":44,"phone":45,"phoneExt":10,"email":46},{"name":38,"role":40,"phone":10,"phoneExt":10,"email":10},{"type":168,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[170,173,175],{"name":171,"class":172},"National Cancer Institute (NCI)","NIH",{"name":174,"class":6},"Canary Foundation",{"name":176,"class":177},"CureBRCA","UNKNOWN","100398760","prostate-cancer-screening-for-people-at-genetic-risk-for-aggressive-disease-patrol-study-100398760",false,"NCT04472338","Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study","PATROL: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease","Inclusion Criteria:\n\n* People with prostates ≥40 years of age\n* Documented germline pathogenic variant in known or suspected genes associated with prostate cancer risk.\n\nExclusion Criteria:\n\n* Prior diagnosis of prostate cancer\n* Medical contraindication to any of the study procedures (e.g., prostate biopsy)\n* For all cancer types except non-melanoma skin cancer, any cancer treatment with curative intent within the past 12 months (e.g., surgery, radiation, chemotherapy, immunotherapy)\n* Prior or concurrent participation in an interventional clinical trial aimed at preventing cancer for people with germline variants associated with increased prostate cancer risk\n* Unable to provide written informed consent\n* Unable or unwilling to complete clinical care and study procedures as indicated by the study protocol.",true,"MALE","40 Years",{"count":189,"type":190},450,"ESTIMATED","OBSERVATIONAL","This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and\u002For tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.",[194],"Prostate Carcinoma","2026-05-13",{"date":197,"type":198},"2026-05-15","ACTUAL",{"date":200,"type":198},"2020-05-21",{"date":202,"type":190},"2030-08-31",{"name":5,"class":6},8]